Recent developments to share with you

Good News | Kangchuanji Pharmaceutical’s Sildenafil Citrate Orally Disintegrating Tablets Have Been Approved for Market Launch

2026-06-29


According to the drug approval document delivery information released by the NMPA, sildenafil citrate orally disintegrating tablets from Nanjing Kangchuanji Pharmaceutical Technology Co., Ltd. have been approved for marketing as a Class 4 generic drug under the new chemical drug registration classification, and are deemed to have passed the consistency evaluation.


Sildenafil citrate orally disintegrating tablets are indicated for the treatment of erectile dysfunction. These tablets do not require water; they dissolve rapidly in the mouth within seconds and provide a quick onset of action, meeting the needs of patients who seek convenient, fast-acting, and discreet oral medications, thereby offering a more flexible and diverse range of treatment options.

Sildenafil was the world’s first PDE5 inhibitor approved for the treatment of erectile dysfunction (ED). Its mechanism of action involves the selective inhibition of PDE5, which increases intracavernosal levels of cyclic guanosine monophosphate (cGMP), thereby relaxing smooth muscle and promoting blood inflow to achieve an erection. Numerous clinical studies and large‑scale real‑world data have consistently demonstrated that sildenafil exhibits significant efficacy and a favorable safety profile across a wide range of etiologies of ED.

Image
 

Keywords:

Related information

Bountiful Results | January–July 2026: Kangchuanji Pharmaceutical, in collaboration with multiple pharmaceutical companies, secured approval or passed the evaluation for 15 product specifications.

From January to July 2026, Nanjing Kangchuanji Pharmaceutical Technology Co., Ltd., leveraging its deep-rooted pharmaceutical R&D expertise and mature end-to-end CDMO capabilities, has provided robust support for the innovative R&D and commercialization of its partner companies, achieving further regulatory‑review milestones in collaboration with multiple partners. According to the NMPA’s public announcement of drug approval documents, a total of 12 drug products (covering 15 specifications) have been successfully approved or passed consistency evaluation, demonstrating significant results in translating innovative research into tangible outcomes.

2026-08-04

CDE Announcement: Updated Guidelines for Pediatric Medicines! “Technical Guidance on the Application of Physiologically Based Pharmacokinetic Models in Drug Development for Pediatric Populations (Draft for Public Comment)”

On August 17, the CDE released a draft of the “Technical Guidance for the Application of Physiologically Based Pharmacokinetic Models in Pediatric Drug Development” for public comment.

2024-10-27

Good news keeps pouring in: Jiuzhou Pharmaceutical’s Kangchuanji Pharmaceutical has helped its partner obtain marketing approval for Rosuvastatin–Ezetimibe Tablets (I).

Good news keeps pouring in: Jiuzhou Pharmaceutical’s Kangchuanji Pharmaceutical has helped its partner obtain marketing approval for Rosuvastatin–Ezetimibe Tablets (I).

2026-07-03